ライフサイエンスコーパス: intrapartum

1 on escape HIV-1 variants occurs in utero and intrapartum.

2 infected in utero than in children infected intrapartum.

3 wo mothers transmitted multiple env variants intrapartum.

4 HIV-1) quasispecies transmitted in utero and intrapartum.

5 other transmitted a single major env variant intrapartum.

6 ransmission occurs late in utero rather than intrapartum.

7 nce in mean scores 0.48 [95% CI 0.41-0.55]), intrapartum (0.28 [0.18-0.37]), hospital-based postnatal

8 smission: seven in utero (448 assessed), two intrapartum (18 assessed), and five during the early pos

9 y assigned to azithromycin received a single intrapartum 2 g oral dose.

10 .0%)], placental conditions [31 (9.1%)], and intrapartum [28 (8.2%)].

11 -17 (18.8% of the cases) was overrepresented intrapartum (35.2%; odds ratio, 5.1 [95% confidence inte

12 intervention; 79.2%, control; p = 0.12) and intrapartum (41.4%, intervention; 48.5%, control; p = 0.

13 r antepartum (49.8% versus 45.1%, p = 0.37), intrapartum (69.9% versus 59.8%, p = 0.18), or postpartu

14 had higher mortality than did those infected intrapartum (70% vs. 37% within 2 years), while no signi

15 infections were more likely to have received intrapartum ampicillin than were those with ampicillin-s

16 Stillbirths occurring intrapartum and early in gestation were more common in n

17 he safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated

18 antenatally and those that developed in the intrapartum and early post-partum period.

19 effect of a quality improvement package for intrapartum and immediate newborn care on stillbirth and

20 rs received a 200-mg single oral dose of NVP intrapartum and infants received either 2-mg/kg oral dos

21 provides HIV-positive women prompt access to intrapartum and neonatal antiretroviral prophylaxis, pro

22 rnal morbidity, pregnancy complications, and intrapartum and neonatal outcomes before and during the

23 ctronic fetal heart-rate monitoring modifies intrapartum and neonatal outcomes.

24 rred in the background of improved household intrapartum and newborn care practices.

25 At 90% coverage, intrapartum and postnatal packages have similar effects

26 HIV-1) transmission occurs during gestation, intrapartum and postpartum (by breast-feeding), 50-70% o

27 Reported overall postpartum and specific intrapartum and postpartum complications were significan

28 d at 28-38 weeks gestation to receive 1 of 3 intrapartum and postpartum regimens: (A) zidovudine plus

29 inistered to the mother during pregnancy and intrapartum and to the infant in the neonatal period has

30 based on the literature, including maternal, intrapartum, and infant characteristics.

31 common cause of neonatal mortality--preterm, intrapartum, and infection-related deaths--by 58%, 79%,

32 to either midwifery continuity of antenatal, intrapartum, and postnatal care (Pilot study Of midwifer

33 study, interventions prioritizing antenatal, intrapartum, and postnatal care could have prevented the

34 l practice guidelines for routine antenatal, intrapartum, and postnatal care, categorising them as re

35 nd improve equity and quality for antenatal, intrapartum, and postnatal care, especially in the poore

36 to assess the association between prenatal, intrapartum, and postnatal factors and the development o

37 age and quality of preconception, antenatal, intrapartum, and postnatal interventions by 2025 could a

38 quality was improved for selected antenatal, intrapartum, and postnatal interventions to benefit preg

39 irect maternal morbidities in the antenatal, intrapartum, and postnatal periods and its association w

40 improved coverage and quality of antenatal, intrapartum, and postnatal services from 2023 to 2030.

41 troviral prophylaxis or treatment (prenatal, intrapartum, and postnatal) was 22.4% in 2002-2005 and 3

42 compared reported prevalence of antepartum, intrapartum, and postpartum complications among recently

43 red pooled and specific reported antepartum, intrapartum, and postpartum complications between study

44 y be improved through optimizing antepartum, intrapartum, and postpartum context- and gestational age

45 normal physiologic changes during pregnancy, intrapartum, and postpartum is the key to managing criti

46 ciency virus type 1 (HIV-1) occurs in utero, intrapartum, and through breastfeeding, with a cumulativ

47 94 women who were HIV positive, received NVP intrapartum, and were previously antiretroviral treatmen

48 The remaining six intrapartum- and two in utero-infected infants had a hom

49 Intrapartum antibiotic chemoprophylaxis (IAP) prevents m

50 e of delivery, but this effect may depend on intrapartum antibiotic exposure.

51 Intrapartum antibiotic prophylaxis (IAP) reduces a newbo

52 Altogether, 20-30% of women receive intrapartum antibiotic prophylaxis (IAP) to prevent seps

53 this risk and how it varies with coverage of intrapartum antibiotic prophylaxis (IAP), used to reduce

54 igh-income contexts, despite declines due to intrapartum antibiotic prophylaxis (IAP).

55 GBS colonization in pregnant women, offering intrapartum antibiotic prophylaxis and point-of-care tes

56 f gestation and, if they are colonized, that intrapartum antibiotic prophylaxis be administered.

57 Although intrapartum antibiotic prophylaxis during labor and deli

58 BS colonization among all pregnant women and intrapartum antibiotic prophylaxis for positive GBS.

59 he implementation of universal screening and intrapartum antibiotic prophylaxis guidelines but late-o

60 he implementation of universal screening and intrapartum antibiotic prophylaxis guidelines but late-o

61 Intrapartum antibiotic prophylaxis is the current mainst

62 rotypes, offering a potential alternative to intrapartum antibiotic prophylaxis to reduce disease bur

63 Studies that reported use of any intrapartum antibiotic prophylaxis were associated with

64 tion, risk of neonatal disease (with/without intrapartum antibiotic prophylaxis), maternal GBS diseas

65 Despite widespread use of intrapartum antibiotic prophylaxis, group B streptococcu

66 occus (GBS) disease with the introduction of intrapartum antibiotic prophylaxis, this pathogen remain

67 k-based approach) to identify candidates for intrapartum antibiotic prophylaxis.

68 47 (69%) studies reported use of any intrapartum antibiotic prophylaxis.

69 , and understanding the effect of widespread intrapartum antibiotic use on long-term infant health.

70 persistent AD was associated with antenatal/intrapartum antibiotic use, food sensitization and some

71 ection is critical because administration of intrapartum antibiotics can significantly reduce transmi

72 3-2004; the percentage of infants exposed to intrapartum antibiotics increased from 26.8% to 31.7%.

73 GBS-IAP and to any other type or duration of intrapartum antibiotics to no antibiotic exposure.

74 Detailed information on delivery method, intrapartum antibiotics, and lifestyle factors was obtai

75 s association did not appear to be biased by intrapartum antibiotics, breastfeeding behaviour, C-sect

76 associations were not strongly influenced by intrapartum antibiotics, breastfeeding, missing data, or

77 ivery mode on gut microbiota, independent of intrapartum antibiotics, by postponing routine antibioti

78 In absence of preventive strategies, such as intrapartum antibiotics, iGBS remains a significant caus

79 sed to GBS-IAP to those exposed to all other intrapartum antibiotics, including surgical prophylaxis.

80 vented by the administration of prophylactic intrapartum antibiotics.

81 tal disease by the wider use of prophylactic intrapartum antibiotics.

82 ng-based approach to identify candidates for intrapartum antibiotics.

83 deaths were prevented in 1998 by the use of intrapartum antibiotics.

84 ture of amniotic membranes, and avoidance of intrapartum antibiotics.

85 Increased use of intrapartum antimicrobial prophylaxis in North America a

86 The role of intrapartum asphyxia in neonatal encephalopathy and seiz

87 ggest that including first stage duration in intrapartum assessments could improve PPH risk identific

88 Gambia and Burkina Faso where women received intrapartum azithromycin (2 g) or placebo.

89 is evidence supports global consideration of intrapartum azithromycin as an economically efficient pr

90 Intrapartum azithromycin decreased E. coli carriage but

91 aimed to evaluate the cost-effectiveness of intrapartum azithromycin for pregnant people planning a

92 do not support routine introduction of oral intrapartum azithromycin for this purpose.

93 revention in Labor Use (A-PLUS) trial showed intrapartum azithromycin for women planning a vaginal bi

94 ironment), there is no data available on how intrapartum azithromycin impacts gut mycobiota developme

95 We aimed to evaluate the effectiveness of intrapartum azithromycin in reducing maternal infection.

96 Intrapartum azithromycin increased the abundance of Cand

97 orm strategies for a wider implementation of intrapartum azithromycin intervention.

98 In most cases, intrapartum azithromycin is a cost-saving intervention f

99 s analysis provides evidence indicating that intrapartum azithromycin is associated with a lower inci

100 We hereby assess the impact of intrapartum azithromycin on gut mycobiota development fr

101 Limited data exist on the effects of intrapartum azithromycin on the prevalence of carriage a

102 Intrapartum azithromycin prophylaxis reduced maternal in

103 In a post hoc analysis of samples from an intrapartum azithromycin randomized clinical trial, we f

104 revention in Labor Use (A-PLUS) trial showed intrapartum azithromycin reduces maternal sepsis or deat

105 In model simulations, intrapartum azithromycin resulted in 1592.0 cases of mat

106 n health-care costs across the A-PLUS sites, intrapartum azithromycin resulted in net savings of US$3

107 We compared the benefits and costs of intrapartum azithromycin versus standard care across 100

108 hildren were defined as infected in utero or intrapartum based on the timing of the first detection o

109 Intrapartum busulfan administration followed by irradiat

110 red out-of-hours had slightly lower rates of intrapartum caesarean section (CS) (12.7% versus 13.4%,

111 eed exists to protect access to high quality intrapartum care and prevent excess deaths for the most

112 and neonatal mortality rate), and quality of intrapartum care before and during the national COVID-19

113 We describe configurations of intrapartum care systems, and focus in particular on whe

114 Improving quality of intrapartum care will reduce intrapartum stillbirth and

115 ge included improving hospital leadership on intrapartum care, building health workers' competency on

116 go on to discuss strategies that complement intrapartum care.

117 n at term is vital for optimal antenatal and intrapartum care.

118 this decrease may be due to improvements in intrapartum care.

119 provision of postpartum care in addition to intrapartum care.

120 llbirths, raising the importance of improved intrapartum care.

121 suggests that implementation of an effective intrapartum-care strategy is an overwhelming priority.

122 gs, planned CD, HR, 0.93; 95% CI, 0.81-1.06; intrapartum CD, HR, 1.07; 95% CI, 0.96-1.21).

123 hazard ratio [HR], 1.17; 95% CI, 1.13-1.22; intrapartum CD, HR, 1.10; 95% CI, 1.05-1.14), ADHD (plan

124 HD (planned CD, HR, 1.17; 95% CI, 1.12-1.23; intrapartum CD, HR, 1.10; 95% CI, 1.05-1.15), and intell

125 ty (planned CD, HR, 1.26; 95% CI, 1.14-1.39; intrapartum CD, HR, 1.17; 95% CI, 1.06-1.28).

126 corded at birth, stratified into planned and intrapartum CD.

127 ars for planned CD, and 16.8 (4.1) years for intrapartum CD.

128 989 (39 191 boys [55.2%]) were delivered via intrapartum CD.

129 to confirm these findings in the setting of intrapartum cesarean delivery.

130 reterm labor: aOR, 2.18; 95% CI, 1.06-4.48), intrapartum (cesarean delivery: aOR, 1.77; 95% CI, 1.01,

131 he evolution of the guidelines for selective intrapartum chemoprophylaxis (SIC) of group B streptococ

132 for prevention of perinatal disease through intrapartum chemoprophylaxis were revised in 2002.

133 p B streptococcus to identify candidates for intrapartum chemoprophylaxis.

134 illbirth (odds ratio comparing antepartum or intrapartum complications with no complication 3.96 [95%

135 vidence that GBS is associated with maternal intrapartum complications.

136 three main causes: infections (0.6 million), intrapartum conditions (0.7 million), and preterm birth

137 were reported during the study: one case of intrapartum convulsion and one case of disseminated intr

138 death, with reassuring trends in deaths from Intrapartum deaths after lockdowns were lifted.

139 A single intrapartum dose of nevirapine for the prevention of mot

140 The intrapartum dose was missed by 12 women, 4 of whom also

141 g of mother-to-child transmission (in utero, intrapartum, early postnatal).

142 to have had intrauterine, 65% (CI, 53%-76%) intrapartum/early postpartum, and 12% (CI, 5%-22%) late

143 The estimated risks for intrauterine, intrapartum/early postpartum, and late postpartum infect

144 transmission risks during the intrauterine, intrapartum/early postpartum, and late postpartum period

145 analysis used as an adjunct to conventional intrapartum electronic fetal heart-rate monitoring did n

146 gment analysis as an adjunct to conventional intrapartum electronic fetal heart-rate monitoring modif

147 546 offspring (1.8%) of mothers who received intrapartum epidural analgesia (incidence rate, 18.8 [95

148 as used to estimate the hazard ratio (HR) of intrapartum epidural analgesia and ASD in offspring.

149 flicting evidence on the association between intrapartum epidural analgesia and risk of autism spectr

150 The crude HR for ASD associated with intrapartum epidural analgesia was 1.30 (95% CI, 1.25-1.

151 Results of this study showed that intrapartum epidural analgesia was associated with a sma

152 n the study, 418 761 (64.4%) were exposed to intrapartum epidural analgesia.

153 In contrast, rate of death after Intrapartum events increased across the first period, fo

154 s of prematurity" (52.9%), "complications of intrapartum events" (15.0%), "congenital malformations"

155 Potential mechanisms include prematurity, intrapartum events, or infections.

156 Any intrapartum exposure to epidural or combined spinal-epid

157 g10 copies per milliliter before therapy and intrapartum exposure to nevirapine were independently as

158 The primary outcome was a composite of intrapartum fetal death, neonatal death, an Apgar score

159 eterm delivery (7.2% vs 16.9%, P = .003) and intrapartum fetal distress (9.1% vs 19.2%, P = .004), wh

160 ith modest increases in preterm delivery and intrapartum fetal distress.

161 plus abnormal fetal growth, malformation, or intrapartum fetal distress.

162 cesarean delivery or instrumental birth for intrapartum fetal distress.

163 In terms of quality of care, intrapartum fetal heart rate monitoring decreased by 13.

164 level is an important objective indicator of intrapartum fetal hypoxia and is used to predict neonata

165 bral palsy and 300 of 378 controls underwent intrapartum fetal monitoring.

166 ation of fetal heart monitoring, advances in intrapartum fetal pulse oximetry, thresholds of acidosis

167 , renal disorders (RRs = 1.54 and 2.56), and intrapartum fever (>100 degrees F) (RRs = 1.17 and 1.69)

168 partum haemorrhage (RR 0.6, 95% CI 0.4-0.9), intrapartum fever (0.4, 0.2-0.9), and use of postpartum

169 IUI was assessed based on intrapartum fever and placenta pathology.

170 luded antepartum or intrapartum haemorrhage, intrapartum fever, postpartum treatment with antibiotics

171 cy, maternal age <20 years, male infant sex, intrapartum fever, prolonged rupture of membranes) and m

172 ould be considered the new gold standard for intrapartum GBS screening.

173 ment group had higher risks of antepartum or intrapartum haemorrhage (RR 0.6, 95% CI 0.4-0.9), intrap

174 ary maternal outcomes included antepartum or intrapartum haemorrhage, intrapartum fever, postpartum t

175 s of PMPA may protect human newborns against intrapartum HIV infection.

176 t mucosal exposure is an important aspect of intrapartum HIV transmission.

177 Antiretroviral regimens can prevent intrapartum HIV transmission; however, these regimens do

178 or to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has l

179 To develop immunoprophylaxis against intrapartum HIV-1 transmission, we used SHIV-vpu+, a chi

180 s the mucosal exposure that can occur during intrapartum HIV-1 transmission.

181 Predictors and prognosis of intrauterine and intrapartum human immunodeficiency virus (HIV) transmiss

182 Single-dose nevirapine reduces intrapartum human immunodeficiency virus 1 type (HIV-1)

183 levant model of perinatal asphyxia providing intrapartum hypoxia in rats.

184 Intrapartum hypoxia-ischemia leading to neonatal encepha

185 se perinatal outcomes potentially related to intrapartum hypoxia.

186 from birth to 24 months in the plasma of 14 intrapartum-infected and 10 uninfected infants born to H

187 We summarise evidence-based antenatal and intrapartum interventions (up to and including clamping

188 ng up the eight proven interventions and two intrapartum interventions would cost about US$1.1 billio

189 Intrapartum intravenous zidovudine (ZDV) prophylaxis is

190 ransmitting in utero (IU) and 9 transmitting intrapartum (IP).

191 The authors examined the relation between intrapartum magnesium sulfate exposure and risk of cereb

192 ug exposure, preeclampsia, chorioamnionitis, intrapartum maternal fever, emergency cesarean delivery,

193 The continuing incidence of intrapartum morbidity may be partly due to antenatal com

194 Intrapartum MTCT was associated with placental microtran

195 viral therapy (ART) reduces intrauterine and intrapartum MTCT, whereas maternal post-partum HIV acqui

196 s less than the decrease in intrauterine and intrapartum MTCT.

197 osure therapy in an infant macaque model for intrapartum MTCT.

198 ction model in neonatal macaques that mimics intrapartum mucosal virus exposure.

199 Intrapartum/neonatal nevirapine significantly lowered HI

200 g population in Uganda compared with a short intrapartum/neonatal zidovudine regimen.

201 68 percent of the women who had not received intrapartum nevirapine (P=0.03).

202 e interval, 8%-23%) of 95 women who received intrapartum nevirapine developed a nevirapine-resistance

203 ed when determining the risks or benefits of intrapartum nevirapine in women receiving antepartum ant

204 the third trimester of pregnancy to receive intrapartum nevirapine or placebo.

205 unknown HIV status, which limits the use of intrapartum nevirapine to prevent mother-to-child transm

206 Women who received intrapartum nevirapine were less likely to have virologi

207 in 49 percent of the women who had received intrapartum nevirapine, as compared with 68 percent of t

208 Among the women who had received intrapartum nevirapine, viral suppression was achieved a

209 ions in pregnant women following single-dose intrapartum nevirapine.

210 rom 32 percent of the women who had received intrapartum nevirapine; the most frequent mutations were

211 A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal

212 ssion was low and no benefit from additional intrapartum/newborn nevirapine was demonstrated when wom

213 artum stillbirths (70 of 95) occurred during intrapartum operative deliveries.

214 omatosis (JORRP) is a rare disease caused by intrapartum or perinatal transmission of human papilloma

215 iciency virus (HIV) infection usually occurs intrapartum or postpartum and results in a higher incide

216 o 1) 500 ml or 2) 1000 ml in the antepartum, intrapartum or postpartum period.

217 s appeared to have acquired infection either intrapartum or postpartum.

218 In 2013, most deaths occurred intrapartum or postpartum.

219 olated from a Zambian infant infected either intrapartum or through breastfeeding.

220 tically depending upon the timing (in utero, intrapartum, or during breastfeeding) and potentially th

221 of obstetric complications in the antenatal, intrapartum, or postnatal period, and any neonatal compl

222 the first 2 months of life, either in utero, intrapartum, or through early breast milk transmission,

223 Data are needed on whether an intrapartum oral dose of azithromycin would reduce mater

224 lysis, exclusion of records with concomitant intrapartum pain management exposures, a complete case a

225 labour; 50% to 93% versus 25% to 86% for any intrapartum pain relief, 19% to 83% versus 10% to 64% fo

226 en are due to vertical transmission, and the intrapartum period appears to provide us with a crucial

227 more than 1 million stillbirths occur in the intrapartum period, despite many being preventable.

228 treatment that can safely be used during the intrapartum period.

229 on HIV transmission during pregnancy or the intrapartum period.

230 that transmission usually occurs during the intrapartum period.

231 cterial infection or colonization during the intrapartum period.

232 ies to disaggregate estimates by antepartum, intrapartum, postpartum, and extended post-partum period

233 ment using procedures such as EXIT (ex-utero intrapartum procedure).

234 h life; however, with the advent of ex-utero intrapartum procedure, a few cases of post-natal surviva

235 hreatening or disabling conditions including intrapartum-related brain injury, severe bacterial infec

236 14.9%, 13.0-16.8]; 0.817-1.057 million), and intrapartum-related complications (0.662 million [10.5%,

237 illion, uncertainty range [UR] 0.916-1.325), intrapartum-related complications (9.4%; 0.717 million,

238 ia (0.191 million [0.168-0.219]; 15.9%), and intrapartum-related events (0.139 million [0.116-0.165];

239 neumonia (0.921 million [0.812 -1.117]), and intrapartum-related events (0.691 million [0.598 -0.778]

240 abnormalities, preterm birth complications, intrapartum-related events, and other causes.

241 ity rates for pneumonia, diarrhoea, neonatal intrapartum-related events, malaria, and measles were re

242 t (QI) package for neonatal resuscitation on intrapartum-related mortality (intrapartum stillbirth an

243 ackage for neonatal resuscitation can reduce intrapartum-related mortality and improve clinical care.

244 The incidence of intrapartum-related mortality was 11.0 per 1,000 births

245 ne (<1%) woman in the labetalol group had an intrapartum seizure and six (1%) neonates (one [<1%] neo

246 This trial compared prophylactic intrapartum single oral dose of 2 g azithromycin versus

247 Intrapartum single-dose (SD) nevirapine (NVP) reduces pe

248 tely 40% of women shortly after they receive intrapartum single-dose nevirapine (SD-NVP).

249 Intrapartum single-dose nevirapine decreases mother-to-c

250 Two women in labor received intrapartum spinal anesthesia from the same anesthesiolo

251 factory competence, we found a lower risk of intrapartum stillbirth (14.2 per 1000 deliveries at >20

252 outcome was perinatal death, which included intrapartum stillbirth (suspected death during labor) an

253 Basic neonatal resuscitation can reduce intrapartum stillbirth and early neonatal mortality, if

254 uscitation on intrapartum-related mortality (intrapartum stillbirth and first day mortality) at hospi

255 ving quality of intrapartum care will reduce intrapartum stillbirth and neonatal mortality, especiall

256 y from 1999 to 2018 to examine rates of term intrapartum stillbirth and risk factors associated with

257 on-based studies to examine the rate of term intrapartum stillbirth in high-income countries and the

258 Delivery-related perinatal death, defined as intrapartum stillbirth or neonatal death unrelated to co

259 The term intrapartum stillbirth rate decreased by 87% (95% CI, 68

260 rs were not associated with the variation in intrapartum stillbirth rates among the time periods.

261 in maternal and obstetric risk factors, term intrapartum stillbirth rates substantially decreased dur

262 The prevalence of term intrapartum stillbirth was higher for individuals who ga

263 The primary composite outcome was intrapartum stillbirth, neonatal death, Apgar score less

264 ctors associated with secular trends of term intrapartum stillbirth.

265 early neonatal mortality, and antepartum and intrapartum stillbirth.

266 The primary study outcome was term intrapartum stillbirth.

267 Three in 4 term intrapartum stillbirths (70 of 95) occurred during intra

268 gested that the steepest slopes for heat for intrapartum stillbirths and associations were stronger d

269 Most intrapartum stillbirths are associated with obstetric em

270 million (range 0.82 million to 1.97 million) intrapartum stillbirths occur yearly.

271 The incidence of intrapartum stillbirths was 8.6 deaths per 1000 births i

272 y perinatal deaths, including antepartum and intrapartum stillbirths, and deaths within 24 h after bi

273 million (uncertainty range 1.2-1.6 million) intrapartum stillbirths, end preventable maternal and ne

274 Yudkin et al. as the optimum denominator for intrapartum stillbirths, fetuses in utero (or "fetuses a

275 y increase mortality risks, particularly for intrapartum stillbirths, raising the importance of impro

276 During the study period, there were 95 term intrapartum stillbirths.

277 lbirths and OR = 1.64 (95% CI 0.74-3.63) for intrapartum stillbirths.

278 ntribution is even higher for late gestation intrapartum stillbirths.

279 wever, running costs are two-fold higher for intrapartum than for postnatal care.

280 (aRR, 0.94; 95% CI, 0.86-1.03) or those with intrapartum transfer of care between a midwife and obste

281 t took place in the hospital after a woman's intrapartum transfer to the hospital.

282 reterm delivery was strongly associated with intrapartum transmission (relative risk, 3.7; 95% confid

283 ered surrogate-nursed kittens suggested that intrapartum transmission may occur.

284 Intrapartum transmission occurred in 24 infants in the z

285 antibodies did not protect infants from the intrapartum transmission of HIV-1.

286 irst week with positive tests later indicate intrapartum transmission.

287 In contrast, intrapartum transmitters were more likely to transmit mi

288 PURPOSE OF REVIEW: The ex-utero intrapartum treatment (EXIT procedure) can be life-savin

289 In this circumstance, the ex-utero intrapartum treatment (EXIT) procedure, which maintains

290 he risk of stillbirth or neonatal death from intrapartum uterine rupture.

291 treatment (EXIT) procedure, which maintains intrapartum uteroplacental support, can be life saving.

292 strategy to prevent postnatal and, possibly, intrapartum virus transmission in a primate model.

293 ection before or during pregnancy (including intrapartum) who deliver liveborn babies at seven sites.

294 mary, MgSO(4) reduced cytokine production in intrapartum women, term and preterm neonates, demonstrat